Targeted Use of Placebo Effects Decreases Experimental Itch in Atopic Dermatitis Patients: A Randomized Controlled Trial
- PMID: 33894061
- DOI: 10.1002/cpt.2276
Targeted Use of Placebo Effects Decreases Experimental Itch in Atopic Dermatitis Patients: A Randomized Controlled Trial
Abstract
Evidence from pain research shows that the effectiveness of active pharmacological treatments can be enhanced by placebo effects. The "open drug administration" is superior to "hidden drug administration." In a randomized controlled trial, we aimed to show that the targeted use of placebo effects increases the efficacy of an antihistamine (dimetindene) infusion in participants with atopic dermatitis. We openly infused dimetindene (drug) in full sight with information (intervention group 1: OPEN-DRUG+INST), openly infused drug with an additional classical conditioning learning experience (intervention group 2: OPEN-DRUG+INST+COND) or infused drug without any information or sight (i.e., hidden administration (control group 1: HIDDEN-DRUG)). Control group 2 received a placebo infusion (saline) declared as dimetindene and also experienced the conditioning experience (PLAC+INST+COND). Itch was experimentally induced with histamine via a skin prick test. Outcome was assessed at the subjective (primary end point: experimental itch intensity, numeric rating scale), and objective level (secondary end point: wheal size, mm2 ). Experimental-induced itch intensity decreased in all groups but at different rates (P < 0.001). The groups with the open administration, whether it was dimetindene or placebo, had significantly stronger reductions in itch compared to the HIDDEN-DRUG group (OPEN-DRUG+INST+COND: P < 0.001; OPEN-DRUG+INST: P = 0.009; and PLAC+INST+COND: P < 0.001). Additional drug conditioning mediated via expectation led to a stronger reduction of itching (P = 0.001). Results on wheal size were similar (P = 0.048), however, no significant difference between the HIDDEN-DRUG group and the PLAC+INST+COND group (P = 0.967) was found. We conclude that specifically generated targeted placebo effects can significantly increase the action of a drug (dimetindene) and should be used in clinical practice.
© 2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Comment in
-
Targeted Use of Placebo Effects Decreases Experimental Itch in Atopic Dermatitis Patients: A Randomized Controlled Trial.Clin Pharmacol Ther. 2022 Mar;111(3):540. doi: 10.1002/cpt.2481. Epub 2021 Nov 16. Clin Pharmacol Ther. 2022. PMID: 34784420 No abstract available.
-
Response to "Targeted Use of Placebo Effects Decreases Experimental Itch in Atopic Dermatitis Patients: A Randomized Controlled Trial".Clin Pharmacol Ther. 2022 Mar;111(3):541. doi: 10.1002/cpt.2483. Epub 2021 Nov 17. Clin Pharmacol Ther. 2022. PMID: 34787923 No abstract available.
References
-
- Amanzio, M., Pollo, A., Maggi, G. & Benedetti, F. Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain 90, 205-215 (2001).
-
- Benedetti, F. Placebo & Effects. Understanding the mechanisms in health and disease. 2nd edn. (Oxford University Press, New York, 2015).
-
- Colloca, L. & Benedetti, F. Placebos and painkillers: Is mind as real as matter? Nat. Rev. Neurosci. 6, 545-552 (2005).
-
- Evers, A.W. et al. Implications of placebo and nocebo effects for clinical practice: expert consensus. Psychother. Psychosom. 87, 204-210 (2018).
-
- Kaptchuk, T.J. & Miller, F.G. Placebo effects in medicine. N. Engl. J. Med. 373, 8-9 (2015).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials